NGM Biopharmaceuticals, Inc.

NGM · NASDAQ
Analyze with AI
12/31/2023
9/30/2023
6/30/2023
3/31/2023
Operating Activities
Net Income-$28-$29-$38-$48
Dep. & Amort.$1$1$1$1
Deferred Tax-$9-$1-$2$0
Stock-Based Comp.$6$6$7$9
Change in WC-$2-$4-$9-$3
Other Non-Cash$9$1$1-$0
Operating Cash Flow-$23-$27-$40-$42
Investing Activities
PP&E Inv.-$0-$0-$0-$1
Net Acquisitions$88-$27-$25-$36
Inv. Purchases-$34-$23-$35-$14
Inv. Sales/Matur.$61$50$59$51
Other Inv. Act.-$88$27$25$36
Investing Cash Flow$27$27$25$36
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$1$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$1$0
Financing Cash Flow$0$0$1$0
Forex Effect$0$0$0$0
Net Chg. in Cash$4-$0-$14-$6
Supplemental Information
Beg. Cash$54$57$72$77
End Cash$59$57$57$72
Free Cash Flow-$23-$27-$40-$42